Appendix 4E & Annual Report
Released
Released
Announcement PDF
Racura Oncology Ltd (formerly known as Race Oncology Limited)
Appendix 4E
Preliminary final report
1 Racura Oncology Ltd
1. Company details
Name of entity: Racura Oncology Ltd (formerly known as Race Oncology Limited)
ABN: 61 149 318 749
Reporting period: For the year ended 30 June 2026
Previous period: For the year ended 30 June 2025
2. Results for announcement to the market
$
Revenues from ordinary activities down 22.2% to 613,291
Loss from ordinary activities after tax attributable to the owners of Racura
Oncology Ltd (formerly known as Race Oncology Limited) up 131.6% to (11,088,270)
Loss for the year attributable to the owners of Racura Oncology Ltd (for-
merly known as Race Oncology Limited) up 131.6% to (11,088,270)
Dividends
There were no dividends paid, recommended or declared during the current financial period.
Comments
The loss for the Company after providing for income tax amounted to $11,088,270 (30 June 2025: $4,787,258).
3. Net tangible assets
Reporting
period
Previous
period
Cents Cents
Net tangible assets per ordinary security 17.44 7.76
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
Racura Oncology Ltd (formerly known as Race Oncology Limited)
Appendix 4E
Preliminary final report
7. Dividend reinvestment plans
Not applicable.
8. Details of associates and joint venture entities
Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
On 6 October 2017, the Company incorporated a subsidiary in Belgium, Race Oncology, Company Number 0682664917.
On 18 June 2025, the Group dissolved its wholly owned subsidiary, Race Oncology SRL/BV, incorporated in Belgium. The
dissolution was completed in accordance with relevant corporate regulations, and the entity has ceased operations.
10. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements have been audited and an unmodified opinion has been issued.
11. Attachments
Details of attachments (if any):
▪ The Annual Report of Racura Oncology Ltd (formerly known as Race Oncology Limited) for the year ended 30 June
2026 is attached.
12. Signed
Signed
Peter Smith
Executive Director/Chair
25 August 2026
Racura Oncology Ltd (formerly known as Race Oncology Limited)
Appendix 4
Preliminary final report
CORPORATE
Directors
Peter Smith Executive Director/Chair
Daniel Tillett Chief Executive Officer and Managing Director
Serge Scrofani Independent Non-Executive Director
Megan Baldwin Independent Non-Executive Director
Company secretary
Peter Webse
Registered office and principal place of business
Level 36, Gateway, 1 Macquarie Place
Sydney NSW 2000
Ph: +61 2 8051 3043
Website: www.racuraoncology.com
Auditor
Hall Chadwick WA
Securities exchange listing
Racura Oncology Ltd (formerly known as Race Oncology Limited) shares
are listed on the Australian Securities Exchange (ASX) (ASX Code: RAC)
Share registry
Automic Group
Level 5, 126 Phillip Street
Sydney NSW 2000
Ph: 1300 288 664
Racura Oncology Ltd
ACN 149 318 749
DIRECTORY
Racura Oncology Ltd (formerly known as Race Oncology Limited)
Appendix 4E
Preliminary final report
3 Racura Oncology Ltd
Chair Letter 1
2026 Key Highlights 4
Directors’ Report 6
Auditor’s Independence Declaration 21
Statement of Financial Position 22
Statement of Profit or Loss
and Other Comprehensive Income
23
Statement of Changes in Equity 24
Statement of Cash Flows 25
Notes to the Financial Statements 26
Directors’ Declaration 46
Independent Auditor’s Report 47
Shareholder Information 52
Glossary 55
CONTENTS
General Information
The financial statements cover Racura Oncology Ltd (formerly known as
Race Oncology Limited) for the year ended 30 June 2026. The financial
statements are presented in Australian dollars, which is Racura Oncology
Ltd's functional and presentation currency.
Racura Oncology Ltd is a listed public company limited by shares,
incorporated and domiciled in Australia.
A description of the nature of the Company’s operations and its principal
activities are included in the directors' report, which is not part of the
financial statements.
The financial statements were authorised for issue, in accordance with a
resolution of directors, on 25 August 2026. The directors have the power
to amend and reissue the financial statements.
1 Racura Oncology Ltd
CHAIR
LETTER
the discovery, supported by a growing body of scientific
evidence, that (E,E)-bisantrene acts as a potent
silencer of the MYC gene, which is a key driver of cancer
growth and one of oncology's most wanted therapeutic
targets.
MYC was discovered in 1982 and is overexpressed in
over 70% of all malignancies, making it one of the most
potentially valuable targets in oncology. Despite that
status, the pharmaceutical industry has struggled to
target MYC due to its lack of a defined three-
dimensional structure, leading to limited to no success
in the clinic. This places (E,E)-bisantrene, which can
rapidly and potently silence the MYC gene, in a
commanding position.
During the year, we reported that we had identified that
bisantrene can form multiple isoforms, of which only
(E,E)-bisantrene has anticancer activity. The
identification of the active isomer is an important
milestone for the Company as it strengthens our
intellectual property position and improves our
understanding of the pharmacology of bisantrene.
Importantly, these discoveries have opened new and
large clinical opportunities for RC220. We now have a
platform asset with the potential to address the many
cancers in which MYC plays a critical role.
Clinical Development Across Three Programs
Racura’s clinical strategy is now driven by the
understanding of the mechanism of action of (E,E)-
bisantrene, allowing us to benefit from the vast amount
of research conducted on MYC, enshrined in over
55,000 scientific publications.
During the year, Racura advanced a development
portfolio spanning acute myeloid leukaemia (AML),
EGFR-mutated non-small cell lung cancer (NSCLC), and
cardioprotection in patients with solid tumours.
Together, these programs provide multiple
opportunities to unlock value from RC220, while
addressing areas of significant unmet medical need.
HARNESS-1: Addressing Drug Resistance in Lung
Cancer
The HARNESS-1 Phase 1a/b clinical trial, evaluating
Dear Fellow Shareholders,
The past twelve months have been
exceptional, with the true potential of RC220
now starting to be understood. Important
discoveries made by our scientists during the
year transformed our understanding of (E,E)-
bisantrene from a misclassified chemo-
therapeutic to arguably one of the most
exciting oncology drugs in clinical
development.
The discovery that (E,E)-bisantrene works via binding to
certain DNA structures called G-quadruplexes has
provided a practicable way to target MYC, a “holy grail”
of oncology and considered by the pharmaceutical
industry to be undruggable. Adding to the progress, we
made fundamental discoveries into the physical
properties of bisantrene that have enabled us to file new
patents including composition of matter claims. These
advances drove the rational expansion of our clinical
strategy, strengthened our intellectual property position,
and created multiple pathways for long-term value
creation.
Equally important, with the strong support of both
existing and new shareholders, we raised over $30
million – providing us with the capital needed to advance
our clinical programs and execute on the opportunities
now before us.
A New Chapter: Goodbye to Race, Hello to Racura
Following shareholder approval at our 2025 Annual
General Meeting, we changed our name from Race
Oncology to Racura Oncology. The new name captures
our heritage but also reflects the fundamental shift in the
prospects for the Company based on the MYC-based
mechanism of action. Our ambitions for the Company
remain unchanged, focused on making a real difference
for cancer patients.
Unlocking the Potential of (E,E)-Bisantrene
The most significant development during the year was
Annual Report 2026 2
RC220 in combination with osimertinib in patients with
EGFR-mutated non-small cell lung cancer, began
during the year.
Following our initial discovery of the mechanism of
action of (E,E)-bisantrene in early 2025, the Company
promptly initiated clinical development of RC220 for
EGRFm NSCLC. Human ethics approval was received in
November 2025, governance approval followed in
March 2026, and the first patient was recruited later
that month. In June, the first patient was treated with
RC220 at Monash Health, marking an important step in
evaluating whether RC220 can help overcome
resistance to EGFR tyrosine kinase inhibitors including
osimertinib.
Resistance to targeted therapies remains one of the
greatest challenges in lung cancer treatment and
represents a substantial unmet medical need. We
believe HARNESS-1 provides an exciting opportunity to
explore RC220's potential in this large patient
population and could open the door to a number of
other significant combinations with other targeted
agents.
The program was further strengthened by our
collaboration with Emory University, led by Professor
Shi-Yong Sun, which provides access to specialised
osimertinib-resistant cancer models and world-leading
expertise in this field.
Building on a Robust AML Foundation
Acute myeloid leukaemia remains a key strategic focus
for Racura. AML is strongly associated with MYC
dysregulation with approximately 90% of AML showing
elevated MYC levels. Importantly, it is also one of the
diseases in which bisantrene has demonstrated
meaningful clinical activity, including receiving
regulatory approval in France in 1988. This unique
history, combined with our growing understanding of
the mechanism of action of (E,E)-bisantrene, continues
to support the rationale for advancing RC220 in this
indication.
During the year, Racura announced planning for a Phase
3 development program designed to bridge RC110 to
RC220; establish evidence of RC220’s expected MYC-
inhibition properties and provide a potentially rapid and
cost-efficient pathway toward regulatory approval. The
Board believes this program, which will be able to directly
and quantitatively assess MYC inhibition in patients, is a
compelling opportunity to leverage decades of clinical
experience with bisantrene in AML.
Advancing the CPACS Trial
Our Cardioprotection and Anticancer Synergy (CPACS)
trial made important progress during the year.
Following review of safety and pharmacokinetic data
from the first patient cohort, the Safety Review
Committee approved escalation to the next planned
RC220 dose level of 80 mg/m². Importantly, no dose-
limiting toxicities or treatment-related safety concerns
were identified, enabling continued dose escalation.
The study is currently underway across Australia, Hong
Kong and soon in South Korea, and aims to demonstrate
RC220's potential to both enhance anticancer activity
and reduce the cardiac toxicity associated with
anthracycline chemotherapy like doxorubicin.
An important achievement during the year was the
development of a novel blood-based molecular assay
designed to explore the cardioprotective effects of
RC220. This test has the potential to generate earlier
insights into cardioprotection during the dose escalation
stage, improve patient safety, and support more efficient
recruitment into the study.
Importantly, through a MYC-based mechanism, we are
now able to explain the mystery of how the combination
of two cancer drugs can increase cancer cell killing whilst
doing less damage to the cardiovascular system.
A Strong Balance Sheet
Our ability to execute this expanded clinical strategy has
been supported by enthusiastic shareholder backing and
disciplined capital management.
Since May 2024, Racura has raised a total of $34.3
million through Bonus and Piggyback Option
conversions, private placements, and option
underwriting initiatives. The full conversion of the
Piggyback Options alone generated $25.2 million,
providing substantial additional capital to advance our
clinical programs.
3 Racura Oncology Ltd
In June 2026, Racura completed a strategic placement
to a specialist institutional investor, raising a further $1
million and establishing a new institutional shareholder
on the register.
The Company also received $2.8 million under the
Australian Government's Research and Development
Tax Incentive program in respect of FY2025 activities.
As at 30 June 2026, Racura held cash and cash
equivalents of $34.3 million, with more than 73% of our
cash expenditure during the year directed towards
research, development and manufacturing activities.
This strong financial position provides funding for all
committed activities into CY2028 and provides the
Company with the runway to deliver key clinical
milestones.
Progress Since Year End
Following the end of the reporting period, the Bellberry
Human Research Ethics Committee approved the
HARNESS-1 trial for expansion beyond Victoria,
enabling additional Australian sites to participate. Chris
O'Brien Lifehouse and Austin Health subsequently
progressed into governance and site start-up activities
The HARNESS-1 Safety Review Committee also
completed its assessment of the first patient cohort,
who received RC220 at 50 mg/m² in combination with
osimertinib.
Outlook
We enter FY2027 in a position of considerable strength.
Racura is funded to support our current activities into
CY2028, advancing three complementary clinical
programs and building a growing body of data
supporting RC220's mechanism of action and broad
therapeutic potential.
Our priorities for the year ahead are tightly focused on
our clinical programs: initiate our pivotal AML program
and continue advancement of the HARNESS-1 and
CPACS trials. At the same time, we will continue to
pursue strategic partnerships, licensing opportunities
and potential commercial transactions that could
accelerate global access to RC220 and maximise
shareholder value.
The progress achieved during 2026 has transformed our
understanding of the opportunity before us. We believe
Racura is now in a better position than at any point in its
history to bring meaningful outcomes for patients and
create value for all shareholders.
On behalf of the Board, I thank our employees,
investigators, scientific and clinical collaborators,
advisers and partners for their dedication throughout the
year. Most importantly, I acknowledge the patients and
families who participate in our clinical programs and
make this work possible.
Finally, I wish to thank both our long-standing
shareholders and our many new investors for your
confidence and support in Racura. We look forward to
updating you on our progress in the coming year as we
continue to advance RC220 and pursue our mission of
silencing cancer.
Sincerely,
Dr Peter Smith
Executive Chair
Racura Oncology
Annual Report 2026 4
2026 KEY
HIGHLIGHTS
Racura announced a composition
of matter intellectual property
(IP) filing for the discovery that
bisantrene can form three
different photoisomers upon
exposure to visible light, allowing
the filing of patents protecting the
composition, manufacture, form-
ulation and use of the active (E,E)-
isoform of bisantrene that had the
potential to provide 20 years of
composition of matter protection
over the active pharmaceutical
ingredient of RC220.
Racura CEO & Managing Director,
Dr Daniel Tillett, presented data
at the European Society for
Medical Oncology (ESMO)
Congress in Berlin. The
presentation summarised results
of preclinical studies and clinical
observations that explore the
dual anticancer and cardio-
protective benefits of (E,E)-
bisantrene when combined with
anthracyclines such as
doxorubicin
Racura announced the discovery
of the anticancer mechanism of
action of (E,E)-bisantrene, found
to function via RNA and DNA G-
quadruplex binding leading to
reduced expression of multiple
cancer genes including MYC.
Racura announced the expansion
of the RC220 clinical program to
cover two major cancer markets;
non-small cell lung cancer and
acute myeloid leukemia. This
expansion built on the recently
discovered mechanism of action
and was subject to the required
capital being successfully raised.
Racura declared that, following
shareholder approval at the 2025
Annual General Meeting, the
Company’s name had changed
from Race Oncology Limited to
Racura Oncology Ltd, signalling a
new era for the Company while
honouring its history.
Racura announced that its
scientists had developed a novel
blood-based molecular test to
assess the cardioprotective
potential of RC220. The test is
intended to be used in the RAC-
010 cardioprotection and
anticancer synergy trial to
quantify the protective effects of
RC220 on molecular pathways
responsible for anthracycline
cardiotoxicity.
02 OCTOBER 2025
16 SEPTEMBER 2025 20 OCTOBER 2025
4 Racura Oncology Ltd
09 DECEMBER 2025
17 NOVEMBER 2025 11 FEBRUARY 2026
5 Racura Oncology Ltd
5 Racura Oncology Ltd
Racura announced that the first
patient had been recruited to the
HARNESS-1 EGFR-mutated lung
cancer trial. The HARNESS-1 trial
is a multi-centre Phase 1a/b study
using circulating tumour DNA to
screen and enrol EGFR-mutated
NSCLC patients receiving
osimertinib, followed by dose
escalation of RC220 in
combination with standard-of-
care maintenance therapy.
Racura announced that the Safety
Review Committee for the CPACS
Phase 1 trial had cleared
escalation to the next RC220
dose level. The committee
identified no treatment-related
safety concerns in Cohort 1
patients and allowed progression
to the Cohort 2 designated dose
level of 80 mg/m² of RC220.
Racura presented at the 2026
American Association for Cancer
Research Annual Meeting. The
team presented MYC gene
silencing data for (E,E)-
bisantrene, showing how it binds
to and stabilises G-quadruplex
structures in the c-MYC promoter
region, leading to silencing of c-
MYC gene expression.
Racura announced that the first
patient had been treated with
RC220 at 50 mg/m² in the Phase
1 HARNESS-1 clinical trial, with
no adverse events observed
during or after the RC220
infusion. HARNESS-1 is
evaluating whether RC220 can be
safely combined with osimertinib
in patients with EGFR-mutated
non-small cell lung cancer.
22 APRIL 2026
31 MARCH 2026 15 MAY 2026
25 JUNE 2026
FY2026 PROVIDED MAJOR DISCOVERIES INTO
THE MECHANISM OF ACTION OF BISANTRENE,
ALLOWING A PRACTICABLE WAY TO TARGET
MYC – THE ‘HOLY GRAIL’ OF ONCOLOGY –
ALONGSIDE FUNDAMENTAL DISCOVERIES INTO
THE PHYSICAL PROPERTIES OF BISANTRENE
ENABLING THE FILING OF NEW PATENTS,
INCLUDING COMPOSITION OF MATTER CLAIMS.
Racura Oncology Ltd
Directors’ report
30 June 2026
Annual Report 2026 6
The directors present their report, together with the financial statements, on Racura Oncology Ltd (referred to hereafter as
the 'Company') for the year ended 30 June 2026.
Information on directors
The following persons were directors of Racura Oncology Ltd during the whole of the financial year and up to the date of
this report, unless otherwise stated:
Peter Smith Executive Director/Chair (appointed as a Non-Executive Director 28 June 2023, ap-
pointed as Executive Director 24 August 2023, appointed as Chair 1 September 2024)
Qualifications BA, MA (Natural Sciences), PhD (Cell Signalling)
Experience Dr Smith has over 35 years of experience in the pharmaceutical and biotech industry,
with a strong focus on therapeutics, especially oncology. He has been involved in projects
at all stages from concept to phase III clinical studies and drug approval. He was previ-
ously the CEO of private biotechnology company Myrio Therapeutics and publicly listed
Australian companies Alchemia and AMRAD. Prior to moving to Australia, Dr Smith co-
founded and was Chief Financial Officer of Onyvax Ltd, a cancer immunotherapy com-
pany based in London. At the start of his career, he was a top-rated Pharmaceuticals
Analyst with UBS and HSBC, being involved in numerous transactions including
LSE/NASDAQ initial public offerings, fundraisings, and M&A. His undergraduate degree,
master’s and doctorate are from the University of Cambridge. He is also currently a Di-
rector of Amala Therapeutics.
Interest in shares and options Personal & related party relevant interests:
▪ 440,019 options exercisable at $1.39, expiring 01 Dec 2028
▪ 273,279 options exercisable at $1.67, expiring 30 Jun 2029
▪ 83,883 options exercisable at $4.69, expiring 24 Nov 2029
▪ 9,433 fully paid ordinary shares
Directorships held in listed
entities
None
Daniel Tillett CEO and Managing Director (appointed as CEO 22 November 2023, appointed as Manag-
ing Director 1 September 2024)
Qualifications BSc (Hons I), PhD (Molecular Genetics & Biochemistry)
Experience Dr Daniel Tillett is the Managing Director and Chief Executive Officer of Racura Oncology.
He is a veteran executive in the biotech industry with more than 25 years of management
experience and leadership in all aspects of commercial operations including strategy, IP
management, sales and marketing, project management, licensing and fundraising. Dr
Tillett is the founder and CEO of Nucleics, a private Australian biotechnology company
producing and selling world-leading DNA sequencing software to the genomics industry.
Previously, he was a Senior Lecturer within the School of Pharmacy at La Trobe University.
Dr Tillett holds a PhD from the University of New South Wales in Molecular Genetics and
Biochemistry. He is Non-Executive Director of Entropy Neurodynamics (ASX: ENP).
Interest in shares and options Personal & related party relevant interests:
▪ 20,269,351 fully paid ordinary shares
▪ 1,534,712 options exercisable at $1.45, expiring 29/11/2028
▪ 3,061,101 options exercisable at $4.25, expiring 29/11/2028
▪ 432,680 options exercisable at $1.67, expiring 30/06/2029
Directorships held in listed
entities
Entropy Neurodynamics Limited (Non-Executive Director, appointed 8 November 2024)
Racura Oncology Ltd
Directors' report
30 June 2026
7 Racura Oncology Ltd
Serge Scrofani Non‑Executive Director (appointed 1 September 2024)
Qualifications BSc (Hons), PhD (Biological Chemistry), MBA (Strategy)
Experience Dr Serge Scrofani has more than 29 years’ experience in the healthcare sector, working
in global roles across research and strategy, and corporate and business development.
After obtaining his PhD in Structural Biology from La Trobe University, Serge undertook
postdoctoral research studies at The University of Melbourne and completed a Fulbright
postdoctoral fellowship at The Scripps Research Institute, La Jolla California. He also
holds an MBA from the Melbourne Business School. He served as Vice President of Strat-
egy & Corporate Development at CSL for 13 years where he played a pivotal role in mul-
tiple strategic initiatives and major M&A transactions. Dr Scrofani is currently CEO & Man-
aging Director of private investment firm FinCap Group Holdings Pty Ltd. He is also a
Board Member of the Burnet Institute and The Centre for Eye Research.
Interest in shares and options Personal & related party relevant interests:
▪ 58,446 options exercisable at $2.05 expiring 25/11/2028
▪ 23,983 options exercisable at $4.69 expiring 24/11/2029
▪ 11,285 fully paid ordinary shares
Directorships held in listed
entities
None
Megan Baldwin Non‑Executive Director (appointed 1 January 2025)
Qualifications BSc (Hons), PhD (Medicine)
Experience Dr Baldwin has more than 25 years of experience working on therapeutic drug develop-
ment programs for oncology and ophthalmic indications. She was the Founder and Chief
Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT). During her tenure of 10
years as CEO and Managing Director of Opthea, the company’s lead asset was advanced
through preclinical studies to global Phase 3 registrational trials. Prior to Opthea, Dr Bald-
win was previously employed at Genentech (now Roche) as a researcher before moving
to Genentech’s commercial division. Dr Baldwin’s experience in oncology drug develop-
ment includes both preclinical and clinical investigation of inhibitors targeting angiogenic
factors involved in tumour growth and spread, as well as management of competitive in-
telligence activities to support Genentech’s early-stage oncology programs. Dr Baldwin
currently serves on the boards of Anaxis Pharma, Gertrude Biomedical, and AusBiotech.
She holds a PhD in Medicine from the University of Melbourne, having conducted her doc-
toral studies at the Ludwig Institute for Cancer Research.
Interest in shares and options Personal & related party relevant interests:
▪ 45,470 options exercisable at $4.69, expiring 24/11/2029
Directorships held in listed
entities
Opthea Ltd (ASX/Nasdaq: OPT) Executive Director (from 1 February 2014 to 15 Novem-
ber 2024); Founder and Chief Innovation Officer (from 1 October 2023 to 1 July 2025);
Invex Therapeutics (from 1 February 2021 to 30 June 2024)
Information on officer holders and Key Management Personnel
Office Holders and Key Management Personnel (KMP) have been in their roles since the start of the financial year to the
date of this report unless otherwise stated.
Peter Webse Company Secretary
Qualifications BBus, FGIA, FCIS
Experience Mr Webse has over 30 years' company secretarial experience and is the director of
Governance Corporate Pty Ltd, a company specialising in providing company secre-
tarial, corporate governance and corporate advisory services.
Racura Oncology Ltd
Directors’ report
30 June 2026
Annual Report 2026 8
Principal activities
Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a dedicated mission to silence
cancer.
Racura’s lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that primarily acts by
stabilising G4-DNA and RNA structures, driving potent silencing of c-MYC, a key cancer gene dysregulated in up to 70% of
all cancers. (E,E)-bisantrene has shown therapeutic activity in cancer patients and has a well-characterised safety profile.
Racura’s discoveries have supported composition-of-matter IP filings that, if granted, could provide up to 20 years of
patent protection for (E,E)-bisantrene.
Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet need across
multiple MYC-driven oncology indications. The Company’s clinical programs include the Phase 3 EMILI trial in acute
myeloid leukaemia, the Phase 1a/b HARNESS trial in combination with osimertinib for EGFR-mutated non-small cell lung
cancer, and the Phase 1a/b CPACS trial in combination with doxorubicin, where Racura aims to deliver both anthracycline
cardioprotection and enhanced anticancer activity.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School
of Medicine, the University of Wollongong and the University of Newcastle. Racura is actively exploring partnerships,
licence agreements and potential commercial merger and acquisition opportunities to accelerate global patient access to
RC220 for patients with cancer across the world.
Outlook
During this financial year, Racura has progressed three clinical trial programs, with two recruiting and treating patients,
reflecting continued momentum across the Company’s expanded development strategy for RC220.
The CPACS trial, evaluating RC220 in combination with doxorubicin in advanced solid tumour patients, has advanced
through its first cohort safety review with no treatment-related safety concerns, and the trial cleared to progress to the
next dose level across Australia, Hong Kong and South Korea. Dose escalation is expected to be completed in FY2027,
allowing progress to the efficacy dose expansion stage.
The HARNESS-1 trial in EGFR-mutated non-small cell lung cancer received all approvals and progressed to the treatment
of the first patient with RC220 in combination with osimertinib. Recruitment is continuing with an expectation that initial
signals of efficacy will be shared in FY2027.
Racura has advanced its Phase 3 acute myeloid leukaemia program, building on the established clinical history of
bisantrene in AML and the Company’s evolving understanding of RC220’s differentiated MYC-silencing mechanism. The
first patient is expected to be recruited within CY2027.
The Company remains well funded to execute its clinical program having $34.3 million in cash and cash equivalents. With
three active clinical programs now progressing and multiple development, regulatory, and clinical milestones expected,
the Company looks forward to updating shareholders with regular news flow over the coming year.
Overview of Company performance
The table below sets out information about Racura's earnings and movements in shareholder wealth for the past five years
up to and including the current financial year.
2026 2025 2024 2023 2022
$ $ $ $ $
Net profit after tax ($'m) (11.09) (4.79) (13.82) (9.92) (11.20)
Share price at year end ($) 2.22 1.18 1.82 1.23 1.95
Basic earnings per share (cents) (6.19) (2.78) (8.40) (6.17) (7.28)
Total dividends (cents per share) - - - - -
Racura Oncology Ltd
Directors' report
30 June 2026
9 Racura Oncology Ltd
Meetings of directors
During the financial year, 9 meetings of directors (including committees of directors) were held. Attendances by each
director during the year were as follows:
Number eligible to attend Number attended
Peter Smith 9 9
Daniel Tillett 9 9
Serge Scrofani 9 9
Megan Baldwin 9 9
Operating results
The operating loss after providing for income tax amounted to $11,088,270 (2025: loss of $4,787,258); net cash used in
operating activities was $8,246,396 (2025: $4,574,413).
Dividends paid or recommended
There were no dividends paid, recommended or declared during the current or previous fi
Share your feedback
Discover